STOUGHTON, Mass. , Dec. 28, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 pending opioid-related

STOUGHTON, Mass. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of the Top Places to Work in Massachusetts in The Boston

STOUGHTON, Mass. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with

STOUGHTON, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences: Jefferies

- Board of Directors Has Authorized $25 Million Accelerated Share Repurchase Program - - Net Income of $8.0 Million and Adjusted EBITDA of $37.3 Million - - Full-Year 2021 Guidance Updated - - Conference Call Scheduled for Today at 4:30 p.m. ET - STOUGHTON, Mass. , Nov.

STOUGHTON, Mass. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today that the Company will host a conference call and live webcast on Thursday, November 4,

STOUGHTON, Mass. , Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were

STOUGHTON, Mass. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the

STOUGHTON, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that its Board of Directors has authorized the repurchase of up to $100 million of the

– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 – – Net Income of $72.8 Million and Adjusted EBITDA of $40.1 Million – – Full-Year 2021 Product Revenue Guidance Updated – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Aug.

STOUGHTON, Mass. , July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021 , at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a

STOUGHTON, Mass. , June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza ® ER and Other Oxycodone Medications

STOUGHTON, Mass. , May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference: Jefferies

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta ® Franchise and Adjusted EBITDA 2021 Guidance Range Raised   – – Colleen Tupper Appointed as Next CFO;  Paul Brannelly will be Leaving the Company to Pursue Other Opportunities   – –

STOUGHTON, Mass. , April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and provide a

– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition – – Collegium Reiterates Previously Issued 2021 Guidance   – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Collegium

STOUGHTON, Mass. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time . The Company will discuss its financial results and

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million – STOUGHTON, Mass. , Jan.